



(12) Translation of
European patent specification

(11) NO/EP 2585064 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/445 (2006.01)
C07D 211/06 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.09.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.05.03
(86)	European Application Nr.	11799027.5
(86)	European Filing Date	2011.06.24
(87)	The European Application's Publication Date	2013.05.01
(30)	Priority	2010.06.24, US, 823039 2011.03.25, US, 201113072616
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, California 94043, US-USA
(72)	Inventor	FAN, Pingchen, 40190 Santa Teresa Common, FremontCalifornia 94539, US-USA GREENMAN, Kevin Lloyd, 463 Bryan Avenue, SunnyvaleCalifornia 94086, US-USA LELETI, Manmohan Reddy, 19608 Pruneridge Avenue, 8304, CupertinoCalifornia 95014, US-USA LI, Yandong, 121 La Quebrada Way, San JoseCalifornia 95127, US-USA POWERS, Jay, 745 Rockaway Beach Avenue, PacificaCalifornia 94044, US-USA TANAKA, Hiroko, 815 Catamaran Street, 1, Foster CityCalifornia 94404, US-USA YANG, Ju, 19608 Pruneridge Avenue, 7304, CupertinoCalifornia 95014, US-USA ZENG, Yibin, 917 Aruba Lane, Foster CityCalifornia 94404, US-USA
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54) Title **C5AR ANTAGONISTS**









(56) References Cited:









WO-A1-2010/075257
WO-A2-2007/051062
BLAGG ET AL.: 'Small, non-peptide C5a receptor antagonists: Part 1' BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS vol. 18, 2008, pages 5601 - 5604, XP025562116
MONK ET AL.: 'Function, structure and therapeutic potential complement C5a receptors' BRITISH JOURNAL OF PHARMACOLOGY vol. 152, 2007, pages 429 - 448, XP008140616






Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>




PATENTKRAV

1. Forbindelse valgt fra gruppen som består av:

 1.394	 1.426
 1.396	 1.460
 1.421	 1.445
 1.428	 1.451

1.438 	1.452 
1.441 	1.499 
1.536  og	1.538 
1.334 	1.371 




1.399 	1.406 
1.412 	1.435 
	1.495 










 1.390	 1.395
 og 1.403	


eller et farmasøytisk akseptabelt salt, hydrat eller rotomer derav.

2. Forbindelse valgt fra gruppen som består av:

5

 1.394	
 1.396	 1.460


1.421 	1.445 
1.426 	
1.428 	1.451 
1.438 	1.452 
1.441 	1.499 




eller et farmasøytisk akseptabelt salt, hydrat eller rotomer deriv..

3. Forbindelse valgt fra gruppen som består:




5



og	 1.495
----	---

eller et farmasøytisk akseptabelt salt, hydrat eller rotomer derav.


4. Forbindelse ifølge krav 1 valgt fra gruppen som består av:

 1.390	 1.395
 og 1.403	

5

eller et farmasøytisk akseptabelt salt, hydrat eller rotomer derav.

5. Forbindelse som er



6. Farmasøytisk sammensetning som omfatter en farmasøytisk akseptabel bærer og en forbindelse ifølge hvilket som helst av kravene 1 til 5.

5

7. Forbindelse ifølge hvilket som helst av kravene 1 til 5 for anvendelse i en framgangsmåte for å behandle et pattedyr som lider av eller er mottakelig for en sykdom eller lidelse som involverer patologisk aktivering av C5a-reseptorer, hvori sykdommen eller lidelsen er en betennelsessykdom eller -lidelse, en kardiovaskulær eller cerebrovaskulær lidelse, en autoimmun lidelse, eller en patologisk senfølge assosiert med insulinavhengig diabetes, mellitus, lupus-nefropati, Heyman-nefritt, membranefritt, glomerulonefritt, kontaktsensitivitetsreaksjoner, eller betennelse som følge av blodkontakt med kunstige overflater.

10

8. Forbindelsen for anvendelsen ifølge krav 7, hvori sykdommen eller lidelsen er en inflammatorisk sykdom eller lidelse.

15

9. Forbindelsen for anvendelsen ifølge krav 8, hvori sykdommen eller -lidelsen er valgt fra gruppen som består av neutropeni, sepsis, septisk sjokk, Alzheimers sykdom, multippel sklerose, slag, inflammatorisk tarmsykdom, aldersrelatert makuladegenerasjon, kronisk obstruktiv lungesykdom, betennelse assosiert med forbrenning, lungeskade, osteoartritt, atopisk dermatitt, kronisk urticaria, iskemi-reperfusjonsskade, akutt respiratorisk stressyndrom, systemisk inflammasjonsresponssyndrom, multippelt organ dysfunksjonssyndrom, vevstransplantatutstøtelse, kreft og hyperakutt utstøtelse av transplanterte organer.

20

25

10. Forbindelsen for anvendelsen ifølge krav 7, hvori sykdommen eller lidelsen er en kardiovaskulær eller cerebrovaskulær lidelse.

5 11. Forbindelsen for anvendelsen ifølge krav 10, hvori sykdommen eller lidelsen er valgt fra gruppen som består av myokardinfarkt, koronar trombose, vaskulær okklusjon, post-kirurgisk vaskulær reokklusjon, arterosklerose, traumatisk sentralnervesystemskade og iskemisk hjertesykdom.

10 12. Forbindelsen for anvendelsen ifølge krav 7, hvori sykdommen eller lidelsen er en autoimmun lidelse.

15 13. Forbindelsen ifølge krav 12, hvori sykdommen eller lidelsen er valgt fra gruppen som består av revmatoid artritt, systemisk lupus erytematose, Guillain-Barre-syndrom, pankreatitt, lupus nefritt, lupus glomerulonefritt, psoriasis, Crohns sykdom, vaskulitt, irritabel tarmsyndrom, dermatomyositt, multippel sklerose, bronkial astma, pemfigus, pemfigoid, sklerodermi, myasthenia gravis, autoimmune hemolytiske og trombocytopeniske tilstander, Goodpastures syndrom, immunovaskulitt, vevstransplantatavvisning og hyperakutt avvisning av transplanterte organer.

20 14. Forbindelsen for anvendelsen ifølge krav 7, hvori sykdommen eller lidelsen er en patologisk senfølge assosiert med gruppen som består av insulinavhengig diabetes, mellitus, lupusnefropati, Heyman-nefritt, membranefritt, glomerulonefritt, kontaktsensitivitetsreaksjoner og betennelse som følge av blodkontakt med kunstige overflater.